- Home
- LCTX vs TVA Comparison
LCTX vs TVA Comparison
Compare LCTX & TVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- TVA
- Stock Information
- Founded
- LCTX 1990
- TVA 2024
- Country
- LCTX United States
- TVA United States
- Employees
- LCTX N/A
- TVA N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- TVA
- Sector
- LCTX Health Care
- TVA
- Exchange
- LCTX Nasdaq
- TVA Nasdaq
- Market Cap
- LCTX 274.0M
- TVA 303.4M
- IPO Year
- LCTX N/A
- TVA 2025
- Fundamental
- Price
- LCTX $1.21
- TVA $10.13
- Analyst Decision
- LCTX Strong Buy
- TVA
- Analyst Count
- LCTX 4
- TVA 0
- Target Price
- LCTX $4.25
- TVA N/A
- AVG Volume (30 Days)
- LCTX 1.5M
- TVA 32.0
- Earning Date
- LCTX 08-12-2025
- TVA 01-01-0001
- Dividend Yield
- LCTX N/A
- TVA N/A
- EPS Growth
- LCTX N/A
- TVA N/A
- EPS
- LCTX N/A
- TVA N/A
- Revenue
- LCTX $10,914,000.00
- TVA N/A
- Revenue This Year
- LCTX N/A
- TVA N/A
- Revenue Next Year
- LCTX $178.80
- TVA N/A
- P/E Ratio
- LCTX N/A
- TVA N/A
- Revenue Growth
- LCTX 76.43
- TVA N/A
- 52 Week Low
- LCTX $0.37
- TVA $9.99
- 52 Week High
- LCTX $1.31
- TVA $10.34
- Technical
- Relative Strength Index (RSI)
- LCTX 59.58
- TVA N/A
- Support Level
- LCTX $1.15
- TVA N/A
- Resistance Level
- LCTX $1.31
- TVA N/A
- Average True Range (ATR)
- LCTX 0.08
- TVA 0.00
- MACD
- LCTX 0.01
- TVA 0.00
- Stochastic Oscillator
- LCTX 70.59
- TVA 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About TVA Texas Ventures Acquisition III Corp Class A Ordinary Share
Texas Ventures Acquisition III Corp is a blank check company.